{
  "symbol": "AQST",
  "company_name": "Aquestive Therapeutics Inc",
  "ir_website": "https://investors.aquestive.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Recent Press Releases",
          "url": "https://investors.aquestive.com/news-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Press Releases \n\n#  Press Releases \n\nPress Releases \n\nYear None20242023202220212020201920182017\n\n2024\n\n11.12.24 \n\n[Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences](/news-releases/news-release-details/aquestive-therapeutics-participate-two-upcoming-investor-3)\n\nWAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (\"Aquestive\" or the \"Company\"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-participate-two-upcoming-investor-3)\n\n11.04.24 \n\n[Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update](/news-releases/news-release-details/aquestive-therapeutics-reports-third-quarter-2024-financial)\n\nAnaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024 AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024 Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channels Finished third \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-reports-third-quarter-2024-financial)\n\n10.25.24 \n\n[Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting](/news-releases/news-release-details/aquestive-therapeutics-present-subsequent-analysis-pivotal-study)\n\nInitial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injection Data demonstrates Anaphylm offers a consistent and permissive method of drug delivery in anaphylaxis management \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-present-subsequent-analysis-pivotal-study)\n\n10.24.24 \n\n[Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film](/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)\n\nCompleted OAS challenge study meets both primary and secondary endpoints Demonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration Pharmacokinetic (PK) profile after allergen exposure comparable to non-allergen PK profile On track for a pre-NDA meeting on \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)\n\n10.21.24 \n\n[Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET](/news-releases/news-release-details/aquestive-therapeutics-report-third-quarter-2024-financial)\n\nWARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-report-third-quarter-2024-financial)\n\n09.27.24 \n\n[Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day](/news-releases/news-release-details/aquestive-therapeutics-spotlights-its-innovative-epinephrine)\n\nAnnounces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film Outlines the development strategy for the Company’s next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-spotlights-its-innovative-epinephrine)\n\n09.09.24 \n\n[Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th](/news-releases/news-release-details/aquestive-therapeutics-hold-virtual-investor-day-provide)\n\nWARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it will \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-hold-virtual-investor-day-provide)\n\n08.22.24 \n\n[Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences](/news-releases/news-release-details/aquestive-therapeutics-participate-two-upcoming-investor-2)\n\nWARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-participate-two-upcoming-investor-2)\n\n08.14.24 \n\n[Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™](/news-releases/news-release-details/aquestive-therapeutics-comments-recent-fda-approval-non)\n\nApplauds first FDA approval of non-injection-based epinephrine device Reiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine) Sublingual Film to the FDA in the first quarter of 2025 WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-comments-recent-fda-approval-non)\n\n08.06.24 \n\n[Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update](/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2024-financial)\n\nLate-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated \n\n[Read More »](/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2024-financial)\n\nDisplaying 1 - 10 of 31 \n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        }
      ]
    },
    {
      "section_name": "Events and Presentations",
      "links": [
        {
          "title": "Q3 2024 Aquestive Therapeutics, Inc. Earnings Conference Call",
          "url": "https://investors.aquestive.com/events/event-details/q3-2024-aquestive-therapeutics-inc-earnings-conference-call",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Events and Presentations \n\n## Q3 2024 Aquestive Therapeutics, Inc. Earnings Conference Call\n\n###  11.05.24 at 8:00 AM EST \n\n[Click here for webcast](https://edge.media-server.com/mmc/p/qis5tq2c)\n\n#### Supporting Materials\n\n[View Presentation](/static-files/62beeb85-8c9a-450f-985e-9d1fc953115f \"Q3 2024 Supplemental Earnings Material- Final.pdf\") 829.6 KB\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        },
        {
          "title": "Q2 2024 Aquestive Therapeutics, Inc. Earnings Conference Call",
          "url": "https://investors.aquestive.com/events/event-details/q2-2024-aquestive-therapeutics-inc-earnings-conference-call",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Events and Presentations \n\n## Q2 2024 Aquestive Therapeutics, Inc. Earnings Conference Call\n\n###  08.07.24 at 8:00 AM EDT \n\n[Click here for webcast](https://edge.media-server.com/mmc/p/xifcbhz2)\n\n#### Supporting Materials\n\n[View Presentation](/static-files/945bbb84-6b56-4d51-94fc-f3208ffa9af9 \"Q2 2024 Supplemental Earnings Material - Final.pdf\") 740.6 KB\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        },
        {
          "title": "Q1 2024 Aquestive Therapeutics, Inc. Earnings Conference Call",
          "url": "https://investors.aquestive.com/events/event-details/q1-2024-aquestive-therapeutics-inc-earnings-conference-call",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Events and Presentations \n\n## Q1 2024 Aquestive Therapeutics, Inc. Earnings Conference Call\n\n###  05.08.24 at 8:00 AM EDT \n\n[Click here for webcast](https://edge.media-server.com/mmc/p/dikoe7g8)\n\n#### Supporting Materials\n\n[View Presentation](/static-files/dfe8a548-1a66-4f26-a236-76b4b1330ef3 \"Q1 2024 Supplemental Earnings Material May 7 - Final 745PM.pdf\") 468.7 KB\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        },
        {
          "title": "Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th",
          "url": "https://investors.aquestive.com/events/event-details/aquestive-therapeutics-hold-virtual-investor-day-provide-pipeline-updates",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Events and Presentations \n\n## Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th\n\n###  09.27.24 at 8:00 AM EDT \n\n[Click here for webcast](https://aquestive-adrenaverse-epinephrine-prodrug-platform-investor-day.open-exchange.net/registration)\n\n#### Supporting Materials\n\n[View Presentation](/static-files/765c0cc9-d679-437f-bdca-f056ebe1e402 \"Investor Day Presentation 9-26-24 - Final Version.pdf\") 4.1 MB\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        },
        {
          "title": "H.C. Wainwright 26th Annual Global Investor Conference",
          "url": "https://investors.aquestive.com/events/event-details/hc-wainwright-26th-annual-global-investor-conference",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Events and Presentations \n\n## H.C. Wainwright 26th Annual Global Investor Conference\n\n###  09.09.24 at 8:30 AM EDT \n\n[Click here for webcast](https://journey.ct.events/view/41658a9c-b78f-4d57-8333-9f5558125364)\n\n#### Supporting Materials\n\n[View Presentation](/static-files/12c94ba6-0b0d-4a4b-99f8-d610c0954b06 \"Aquestive HCWainwright - September 2024 Conference- 9-9-24.pdf\") 1.8 MB\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.aquestive.com/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  SEC Filings \n\n#  SEC Filings \n\n## SEC Filings\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -202420232022202120202019201820172016201520142013201220112010200920082007\n\n- Any -\n\nItems per page 102550\n\n10\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | View  \n---|---|---|---  \nNov 27, 2024 | Statement of changes in beneficial ownership of securities | [4](/sec-filings/sec-filing/4/0001214659-24-019685) |  [0001214659-24-019685.pdf](/static-files/09f00cbf-8100-463b-acfc-d86380e06645) [0001214659-24-019685.rtf](/static-files/b17d5a7b-3003-492d-9de1-882172576943) [0001214659-24-019685.xls](/static-files/02ddb1e7-8907-4929-a623-c1cd04b19f49) [View HTML](/node/10916/html)  \nNov 14, 2024 | An amendment to the SC 13G filing | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001172661-24-005118) |  [0001172661-24-005118.pdf](/static-files/b6cbb41e-6384-4e79-bb6b-1aa9aeccbe7c) [0001172661-24-005118.rtf](/static-files/c4f18220-fb66-454b-878e-42cb0991397b) [0001172661-24-005118.xls](/static-files/bb2b953d-89c8-4d35-9e4f-fa0657941bd6) [View HTML](/node/10911/html)  \nNov 08, 2024 | A statement of beneficial ownership of common stock by certain persons | [SC 13G](/sec-filings/sec-filing/sc-13g/0002012383-24-004005) |  [0002012383-24-004005.pdf](/static-files/ae46bf3b-e0dd-43cb-942d-c12d8d19be8d) [0002012383-24-004005.rtf](/static-files/17df10e8-12cb-4b2d-b01d-7f86d2d95298) [View HTML](/node/10901/html)  \nNov 07, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-046223) |  [0001628280-24-046223.pdf](/static-files/63efd2aa-1859-4c04-973f-5a4e72e8a318) [0001628280-24-046223.rtf](/static-files/d4350adb-746a-4e22-9313-a47a2175f2a0) [0001628280-24-046223.xls](/static-files/95a47700-6cd3-4170-bd65-fdf62f555ee9) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-046223) [View HTML](/node/10896/html)  \nNov 06, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-045687) |  [0001628280-24-045687.pdf](/static-files/6b824331-2a85-46db-8218-880b463c8a44) [0001628280-24-045687.rtf](/static-files/9009b3dc-85b6-4a8f-8b7c-8a34ad9c5ff3) [0001628280-24-045687.xls](/static-files/c21fde4c-d965-4ea3-b37e-e876b6552700) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-045687) [View HTML](/node/10891/html)  \nNov 04, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-045028) |  [0001628280-24-045028.pdf](/static-files/cabe5899-3480-48a0-870c-f75b39232b8e) [0001628280-24-045028.rtf](/static-files/0d196a54-b3e3-419c-ac03-32107fe143fb) [0001628280-24-045028.xls](/static-files/9099eb40-3932-4cde-aa63-08833c259349) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-045028) [View HTML](/node/10881/html)  \nNov 04, 2024 | Quarterly report which provides a continuing view of a company's financial position | [10-Q](/sec-filings/sec-filing/10-q/0001628280-24-045030) |  [0001628280-24-045030.pdf](/static-files/34606010-4863-4dd6-87a5-a4dbda2e164a) [0001628280-24-045030.rtf](/static-files/749341f9-1162-4c73-b4f7-1650c35322bd) [0001628280-24-045030.xls](/static-files/cf0e1ba5-e430-44e6-8eac-a71bf2d8bb4c) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001628280-24-045030) [View HTML](/node/10886/html)  \nOct 25, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-043761) |  [0001628280-24-043761.pdf](/static-files/e3f98861-3b17-42e7-9760-151c08dbd418) [0001628280-24-043761.rtf](/static-files/dc7d05ea-4b2f-484b-b944-7b40c6814132) [0001628280-24-043761.xls](/static-files/58cd06ea-a55a-4645-ad18-8aad162f1785) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-043761) [View HTML](/node/10866/html)  \nOct 24, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-043505) |  [0001628280-24-043505.pdf](/static-files/083d0492-c638-47f4-92db-a703fda1ef79) [0001628280-24-043505.rtf](/static-files/94b0cab7-0d92-4fec-a084-357041bfc63f) [0001628280-24-043505.xls](/static-files/e11e0e9c-1682-4447-af8f-dc4d131b9e93) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-043505) [View HTML](/node/10856/html)  \nOct 22, 2024 | A statement of beneficial ownership of common stock by certain persons | [SC 13G](/sec-filings/sec-filing/sc-13g/0002012383-24-001599) |  [0002012383-24-001599.pdf](/static-files/83dce73f-77b3-4240-81d7-fb2d0260e1be) [0002012383-24-001599.rtf](/static-files/c1430628-b071-488e-bf93-82ae080996e6) [View HTML](/node/10841/html)  \n  \nDisplaying 1 - 10 of 523 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        }
      ]
    },
    {
      "section_name": "Financial Information",
      "links": [
        {
          "title": "Analyst Coverage",
          "url": "https://investors.aquestive.com/financial-information/analyst-coverage",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img/svg/aquestive-logo.svg) ](https://aquestive.com/)\n\n![](/sites/g/files/knoqqb89071/themes/site/nir_pid2684/dist/img//svg/close_btn.svg)\n\n  * [About Us](https://aquestive.com/about-us/)\n    * [Leadership](https://aquestive.com/about-us/#leadership)\n    * [Board of Directors](https://aquestive.com/about-us/#board-of-directors)\n    * [Scientific Advisory Board](https://aquestive.com/about-us/#scientific-advisory-board)\n  * [Our Medicines](https://aquestive.com/medicines/)\n    * [Licensed Commercial Medicines](https://aquestive.com/medicines/licensed-commercial-medicines/)\n    * [Expanded Access Policy](https://aquestive.com/content/uploads/Policy-on-Access-to-Unapproved-or-Uncommericalized-Medicines-.pdf)\n  * [Pipeline](https://aquestive.com/pipeline/)\n    * [Clinical Trials](https://aquestive.com/pipeline/clinical-trials/)\n    * [Anaphylm™](https://aquestive.com/anaphylm/)\n    * [Libervant™](https://aquestive.com/pipeline/diazepam/)\n  * [PharmFilm](https://aquestive.com/innovative-drug-delivery-pharmfilm/)\n    * [PharmFilm® Technology](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [PharmFilm® Overview](https://aquestive.com/innovative-drug-delivery-pharmfilm/#overview)\n      * [Delivery Methods](https://aquestive.com/innovative-drug-delivery-pharmfilm/#delivery)\n      * [Science](https://aquestive.com/innovative-drug-delivery-pharmfilm/#science)\n      * [Advantages](https://aquestive.com/innovative-drug-delivery-pharmfilm/#advantages)\n    * [Transmucosal Expertise](https://aquestive.com/innovative-drug-delivery-pharmfilm/transmucosal-expertise/)\n    * [Collaborations](https://aquestive.com/collaborations/)\n      * [In-licensing](https://aquestive.com/collaborations/#in-licensing)\n      * [Out-licensing](https://aquestive.com/collaborations/#out-licensing)\n    * [Development & Licensee Services](https://aquestive.com/collaborations/development-and-licensee-services/)\n      * [Overview](https://aquestive.com/collaborations/development-and-licensee-services/#overview)\n      * [Formulation Development](https://aquestive.com/collaborations/development-and-licensee-services/#formulation-development)\n      * [Analytical](https://aquestive.com/collaborations/development-and-licensee-services/#analytical)\n      * [Tech Transfer](https://aquestive.com/collaborations/development-and-licensee-services/#tech-transfer)\n      * [Preclinical](https://aquestive.com/collaborations/development-and-licensee-services/#pre-clinical)\n      * [Clinical](https://aquestive.com/collaborations/development-and-licensee-services/#clinical)\n      * [Regulatory](https://aquestive.com/collaborations/development-and-licensee-services/#regulatory)\n      * [Commercial](https://aquestive.com/collaborations/development-and-licensee-services/#commercial)\n  * [Our Responsibility](https://aquestive.com/our-responsibility/)\n    * [Working With Healthcare Professionals](https://aquestive.com/our-responsibility/working-with-health-care-professionals/)\n    * [Code of Conduct](https://aquestive.com/our-responsibility/code-of-conduct/)\n    * [Sales And Marketing](https://aquestive.com/our-responsibility/sales-and-marketing/)\n    * [Corporate Compliance](https://aquestive.com/our-responsibility/corporate-compliance/)\n    * [ESG Report 2022](https://aquestive.com/our-responsibility/esg-2022-report/)\n  * [Investors](/)\n    * [Home](/)\n    * [Press Releases](/news-releases)\n    * [Events and Presentations](/events-and-presentations)\n    * [Scientific Events](https://aquestive.com/newsroom/#events)\n    * [Corporate Governance](/corporate-governance)\n    * [SEC Filings](/sec-filings)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/financial-information/analyst-coverage)\n\n\n\n#  Analyst Coverage \n\n#  Analyst Coverage \n\nAnalyst Coverage \n\nJames Molloy \n\nAlliance Global Partners\n\nRaghuram Selvaraju, Ph.D. \n\nHC Wainwright & Co.\n\nJason Butler \n\nJMP Securities\n\nThomas Flaten \n\nLake Street Capital Markets\n\nRoanna Ruiz \n\nLeerink Partners\n\nFrancois Brisebois \n\nOppenheimer\n\nDavid Amsellem \n\nPiper Sandler\n\nGary Nachman \n\nRaymond James \n\nAquestive Therapeutics is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Aquestive Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aquestive Therapeutics or its management. Aquestive Therapeutics does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\n[ Email Alerts ](/email-alerts)\n\n**Email Alerts**\n\n[ Investor Contact ](/investor-contact)\n\n**Investor Contact**\n\n[ Investor FAQs ](/investor-faqs)\n\n**Investor FAQs**\n\n[ RSS Feeds ](/rss-feeds)\n\n**RSS Feeds**\n"
        }
      ]
    }
  ]
}